News

FUJIFILM Corporation announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will…
Read More...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for cobas MPXV for use on the cobas 6800/8800 Systems. The test is a real time…
Read More...

IVERIC bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel…
Read More...

Takeda announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute…
Read More...

Alexion, AstraZeneca Rare Disease, announced the completion of its acquisition of LogicBio Therapeutics, Inc. The acquisition creates an opportunity to accelerate Alexion’s growth in…
Read More...

Horizon Therapeutics plc announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop…
Read More...

Ascletis Pharma Inc. announces the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for the in-house developed oral…
Read More...

Idorsia Ltd, specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options, and Simcere Pharmaceutical Group Ltd, an…
Read More...

Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models of inflammatory bowel disease (IBD). The…
Read More...

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, and Affini-T Therapeutics, a biotechnology company unlocking the…
Read More...

NextCure, Inc. and LegoChem Biosciences, Inc. announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two…
Read More...

Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, announced the company has…
Read More...

Exscientia plc and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of…
Read More...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients with…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or…
Read More...

AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorisation in the European Union (EU) for…
Read More...

ImmunoGen Inc. announced that the US Food and Drug Administration (FDA) has granted accelerated approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients…
Read More...

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration…
Read More...